New myeloma study

DREAMM 7 – A Multicentre, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belnatamab mafadotin (GSK2857916), Bortezomib, and Dexamethasone Compared with the Combination of Daratumumab, Bortezomib and Dexamethasone in Participants with Relapsed/Refractory Multiple Myeloma

Recruitment to start from end of September (Phase III study from GSK)

Information and how to apply will be available on the ClinTrial Refer app. See information on downloading the app here.